Publication dates

1-10 of about 900 reports for Phase Iii Clinical Trial

Purchase Reports From Reputable Market Research Publishers

Pharmacovigilance Market [Clinical Trial Phases (Pre-Clinical Studies, Phase I, Phase II, Phase III, Phase IV or Post-Marketing Surveillance) and Service Providers (In-House and Contract Outsourcing] - Global Industry Analysis, Size, Share, Growth, Trends

Pharmacovigilance Market Clinical Trial Phases Pre Clinical Studies Phase I Phase II Phase III Phase IV or Post Marketing Surveillance and Service Providers In House and Contract Outsourcing Global Industry Analysis Size Share Growth Trends

  • $ 4 795
  • Industry report
  • February 2014
  • by Transparency Market Research

A rising tide of regulatory expectations tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market An upsurge

Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evolocumab Acute Coronary Syndrome Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • July 2014
  • by Global Data

Evolocumab Acute Coronary Syndrome Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report Evolocumab Acute Coronary Syndrome Forecast

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014

Dysbetalipoproteinemia Type III Hyperlipoproteinemia Global Clinical Trials Review H1 2014

  • $ 2 500
  • Industry report
  • May 2014
  • by Global Data

Dysbetalipoproteinemia Type III Hyperlipoproteinemia Global Clinical Trials Review H1 2014 Summary GlobalData s clinical trial report Dysbetalipoproteinemia Type III Hyperlipoproteinemia Global

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014

Mucopolysaccharidosis III MPS III Sanfilippo Syndrome Global Clinical Trials Review H1 2014

  • $ 2 500
  • Industry report
  • May 2014
  • by Global Data

Mucopolysaccharidosis III MPS III Sanfilippo Syndrome Global Clinical Trials Review H1 2014 Summary GlobalData s clinical trial report Mucopolysaccharidosis III MPS III Sanfilippo Syndrome

PCSK9 and Other Novel Hypercholesterolemia Drugs Market, 2014 - 2024

PCSK9 and Other Novel Hypercholesterolemia Drugs Market 2014 2024

  • $ 1 899
  • Industry report
  • September 2014
  • by Roots Analysis Private Ltd.

INTRODUCTION Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol lowering drugs in the market Out of all the available options statins have

Oral Oncolytics Series: Leukemia, 2014 - 2024

Oral Oncolytics Series Leukemia 2014 2024

  • $ 1 899
  • Industry report
  • May 2014
  • by Roots Analysis Private Ltd.

INTRODUCTION Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry Oral targeted therapeutics has attracted many drug developers due to the ease of administration

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

Hepatitis C Market Forecast HCV Drugs Clinical Trials Hepatitis C Pipeline Drugs Sales Forecast Worldwide

  • $ 1 290
  • Industry report
  • July 2013
  • by Renub Research

Hepatitis C Market Overview Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012 Hepatitis C virus HCV infection is a complex public health problem

RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review

RedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • February 2015
  • by Global Data

Summary RedHill Biopharma Ltd RedHill is a biopharmaceutical company It intends to acquire and develop late clinical stage proprietary drugs for the treatment of gastrointestinal and inflammatory

RedHill Biopharma Ltd. (RDHL) - Medical Equipment - Deals and Alliances Profile

RedHill Biopharma Ltd RDHL Medical Equipment Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2015
  • by Global Data

Summary RedHill Biopharma Ltd RedHill is a biopharmaceutical company It intends to acquire and develop late clinical stage proprietary drugs for the treatment of gastrointestinal and inflammatory

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab Psoriasis Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Tildrakizumab Psoriasis Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic systemic inflammatory and chronic skin disorder with an overall prevalence of 2 3 worldwide

About 2 800 reports for Phase Iii Clinical Trial

Download Unlimited Documents from Trusted Public Sources

Biopharmaceutical Industry Company Report 2013

  • January 2013
    4 pages
  • Biosimilar  

    Monoclonal Anti  

    Clinical Trial  

  • North America  

    World  

    Europe  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.